{"id":"https://openalex.org/W3201664274","doi":"https://doi.org/10.1016/j.annonc.2021.08.1476","title":"1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma","display_name":"1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma","publication_year":2021,"publication_date":"2021-09-01","ids":{"openalex":"https://openalex.org/W3201664274","doi":"https://doi.org/10.1016/j.annonc.2021.08.1476","mag":"3201664274"},"language":"en","primary_location":{"id":"doi:10.1016/j.annonc.2021.08.1476","doi":"https://doi.org/10.1016/j.annonc.2021.08.1476","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2021.08.1476","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(21)03705-4/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.annalsofoncology.org/article/S0923-7534(21)03705-4/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034365278","display_name":"Dirk Schadendorf","orcid":"https://orcid.org/0000-0003-3524-7858","observed_orcids":["https://orcid.org/0000-0003-3524-7858"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Schadendorf","raw_affiliation_strings":["Department of Dermatology, West German Cancer Center, Essen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, West German Cancer Center, Essen, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089297467","display_name":"Reinhard Dummer","orcid":"https://orcid.org/0000-0002-2279-6906","observed_orcids":["https://orcid.org/0000-0002-2279-6906"]},"institutions":[{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"R. Dummer","raw_affiliation_strings":["Department of Dermatology, University Hospital Z\u00fcrich, Zurich, Switzerland","Department of Dermatology, University Hospital Zurich; Zurich Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University Hospital Z\u00fcrich, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210100468"]},{"raw_affiliation_string":"Department of Dermatology, University Hospital Zurich; Zurich Switzerland","institution_ids":["https://openalex.org/I4210100468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100713900","display_name":"Caroline Robert","orcid":"https://orcid.org/0000-0002-9493-0238","observed_orcids":["https://orcid.org/0000-0002-9493-0238"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"C. Robert","raw_affiliation_strings":["Dermatology Unit, Institut Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Unit, Institut Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112042373","display_name":"A. Ribas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Ribas","raw_affiliation_strings":["Department of Medicine, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008479799","display_name":"Ryan Joseph Sullivan","orcid":"https://orcid.org/0000-0001-5344-6645","observed_orcids":["https://orcid.org/0000-0001-5344-6645"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R.J. Sullivan","raw_affiliation_strings":["Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111764574","display_name":"Timothy J. Panella","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802076678","display_name":"University of Tennessee Medical Center","ror":"https://ror.org/0277n1841","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802076678"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Panella","raw_affiliation_strings":["Oncology, University of Tennessee Medical Center at Knoxville, Knoxville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, University of Tennessee Medical Center at Knoxville, Knoxville, TN, USA","institution_ids":["https://openalex.org/I2802076678"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002575629","display_name":"Meredith Ann McKean","orcid":"https://orcid.org/0000-0003-0944-7418","observed_orcids":["https://orcid.org/0000-0003-0944-7418"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.A. Mckean","raw_affiliation_strings":["Drug Development Unit, Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Development Unit, Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN, USA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058967910","display_name":"Edgardo S. Santos","orcid":"https://orcid.org/0000-0003-0776-4903","observed_orcids":["https://orcid.org/0000-0003-0776-4903"]},"institutions":[{"id":"https://openalex.org/I63772739","display_name":"Florida Atlantic University","ror":"https://ror.org/05p8w6387","country_code":"US","type":"education","lineage":["https://openalex.org/I63772739"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E.S. Santos","raw_affiliation_strings":["Florida Precision Oncology, Florida Atlantic University, Aventura, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Precision Oncology, Florida Atlantic University, Aventura, FL, USA","institution_ids":["https://openalex.org/I63772739"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109328493","display_name":"Kimberli J. Brill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Brill","raw_affiliation_strings":["Melanoma, Pfizer, La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma, Pfizer, La Jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083634538","display_name":"Anna Polli","orcid":"https://orcid.org/0009-0003-5440-6129","observed_orcids":["https://orcid.org/0009-0003-5440-6129"]},"institutions":[{"id":"https://openalex.org/I4210142120","display_name":"Pfizer (Italy)","ror":"https://ror.org/03htt2d69","country_code":"IT","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210142120"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"A. Polli","raw_affiliation_strings":["Oncology, Pfizer, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Pfizer, Milan, Italy","institution_ids":["https://openalex.org/I4210142120"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108751899","display_name":"Alessandra di Pietro","orcid":"https://orcid.org/0009-0009-1887-6610","observed_orcids":["https://orcid.org/0009-0009-1887-6610"]},"institutions":[{"id":"https://openalex.org/I4210142120","display_name":"Pfizer (Italy)","ror":"https://ror.org/03htt2d69","country_code":"IT","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210142120"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"A. di Pietro","raw_affiliation_strings":["Immuno-Oncology, Pfizer, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immuno-Oncology, Pfizer, Milan, Italy","institution_ids":["https://openalex.org/I4210142120"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5029398339","display_name":"Paolo A. Ascierto","orcid":"https://orcid.org/0000-0002-8322-475X","observed_orcids":["https://orcid.org/0000-0002-8322-475X"]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"P.A. Ascierto","raw_affiliation_strings":["Department of Melanoma, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Melanoma, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy","institution_ids":["https://openalex.org/I4210141868"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":null,"fwci":0.2342,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":{"value":0.43756391,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"32","issue":null,"first_page":"S902","last_page":"S902"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/encorafenib","display_name":"encorafenib","score":0.9800000190734863},{"id":"https://openalex.org/keywords/binimetinib","display_name":"binimetinib","score":1.0},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/braf-v600-mutant-melanoma","display_name":"BRAF V600-mutant melanoma","score":0.9520000219345093},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9190000295639038},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7059999704360962},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.5929999947547913},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.5839999914169312},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.6029999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8181688785552979},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6799929141998291},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5019686222076416},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.4648289680480957},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35884857177734375},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.2820777893066406},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2788066267967224},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.20096686482429504},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.09771916270256042}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.annonc.2021.08.1476","doi":"https://doi.org/10.1016/j.annonc.2021.08.1476","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2021.08.1476","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(21)03705-4/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.annonc.2021.08.1476","doi":"https://doi.org/10.1016/j.annonc.2021.08.1476","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2021.08.1476","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(21)03705-4/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320309577","display_name":"Array BioPharma","ror":"https://ror.org/018axtd57"},{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"},{"id":"https://openalex.org/F4320312140","display_name":"Exelixis","ror":"https://ror.org/01e3jga91"},{"id":"https://openalex.org/F4320314128","display_name":"Les Laboratories Pierre Fabre","ror":"https://ror.org/04hdhz511"},{"id":"https://openalex.org/F4320314605","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320317987","display_name":"Syndax Pharmaceuticals","ror":"https://ror.org/02w9kv048"},{"id":"https://openalex.org/F4320319071","display_name":"Moderna","ror":"https://ror.org/01xm4wg91"},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320322148","display_name":"Eisai","ror":"https://ror.org/04vvh7p27"},{"id":"https://openalex.org/F4320328070","display_name":"Sun Pharma","ror":"https://ror.org/04vnqkx80"},{"id":"https://openalex.org/F4320328456","display_name":"Italfarmaco","ror":"https://ror.org/05xsppr58"},{"id":"https://openalex.org/F4320331540","display_name":"NeraCare","ror":"https://ror.org/018wr9e73"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3201664274.pdf","grobid_xml":"https://content.openalex.org/works/W3201664274.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4379338576","https://openalex.org/W4365512752","https://openalex.org/W7014907485","https://openalex.org/W4295817211","https://openalex.org/W4247590015","https://openalex.org/W4389279884","https://openalex.org/W2973367848","https://openalex.org/W3042405305","https://openalex.org/W4387810940","https://openalex.org/W4403329913"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2021-10-11T00:00:00"}